Location: Newton, MA
Search
Close this search box.
Lumicell Surgeon 1
Illuminate residual
breast cancer
intraoperatively
Discover a brand-new vision in real-time excision
Lumicell Surgeon 2
Illuminate residual
breast cancer
intraoperatively
Discover a brand-new vision in real-time excision
Lumicell Animation 1
PlayPlay
Lumicell Surgeon 2
View the data
Proven effectiveness in a clinical trial setting
previous arrow
next arrow

Investigational system with potential to change current landscape of breast cancer surgery.

How it Works

Transformative technology to evolve the standard of care in cancer surgery

Lumicell is transforming the way you see breast cancer surgery. Our investigational fluorescence imaging technology is designed to illuminate residual breast cancer in real time. The system is indicated for use in patients with breast cancer to assist in the detection of cancerous tissue within the lumpectomy cavity following removal of the primary specimen during lumpectomy surgery.

An investigational system with the potential to change the current landscape of breast cancer surgery

Lumicell News

Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting

Key Studies Examined the Benefits of Intraoperative Imaging Using Investigational Agent LUMISIGHT™ in Combination with Lumicell™ Direct Visualization System (DVS)  ...
Read More

Lumicell Announces FDA Advisory Committee’s Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT™ in the Detection of Cancerous Tissue During Breast Conserving Surgery

NEWTON, Massachusetts - Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer, today announced the Medical Imaging Dru...
Read More

Lumicell Announces Initial Data Demonstrating LUMISIGHT™’s Ability to Detect Tumors Metastasized to Multiple Organs in the Peritoneum

Promising feasibility study results for imaging technology that identified malignant peritoneal tumor metastasis during surgery NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc.,...
Read More

Lumicell Co-Founder Moungi Bawendi Awarded Nobel Prize in Chemistry

Bawendi’s expertise in optics, fluorescent molecules and tissue imaging were instrumental in development of Lumicell Direct Visualization System, which is currently under FDA re...
Read More

Lumicell Announces FDA Acceptance and Priority Review of New Drug Application for LUMISIGHT™ Optical Imaging Agent for Breast Cancer

Premarket Approval application for Lumicell™ Direct Visualization System also accepted by FDA LUMISIGHT and the Lumicell DVS would be the first and only optical imaging...
Read More

Lumicell™ DVS Pivotal Trial Results Published in NEJM Evidence and to Be Presented at ASBrS Assess Safety and Effectiveness of System for Identifying Residual Breast Cancer During Lumpectomy

INSITE Trial included more than 400 patients at 14 leading academic and community cancer centers Intracavity visualization system uses fluorescence imaging designed to id...
Read More